中华检验医学杂志
中華檢驗醫學雜誌
중화검험의학잡지
CHINESE JOURNAL OF LABORATORY MEDICINE
2014年
6期
447-450
,共4页
夏敏%杨静薇%高原%廖雪莲%刘家应%李红%刘青%张泓
夏敏%楊靜薇%高原%廖雪蓮%劉傢應%李紅%劉青%張泓
하민%양정미%고원%료설련%류가응%리홍%류청%장홍
前体细胞淋巴母细胞白血病淋巴瘤%抗原,CD20%预后
前體細胞淋巴母細胞白血病淋巴瘤%抗原,CD20%預後
전체세포림파모세포백혈병림파류%항원,CD20%예후
Precursor cell lymphoblastic leukemia-lymphoma%Antigens,CD20%Prognosis
目的:分析儿童B系急性淋巴细胞性白血病( B-ALL)中CD20表达和临床特点,探索CD20在评估预后中的作用。方法2008年11月至2012年7月上海市儿童医院初诊125例B系儿童急性淋巴细胞性白血病患儿,男79例,女46例,年龄2个月~14岁,所有患儿均应用流式细胞仪进行初诊时的免疫分型和微小残留病变( MRD)筛选,对存在MRD标记的患儿在诱导缓解的第35天进行MRD监测。根据CD20表达将B-ALL患儿分为CD20阳性组和CD20阴性组,对各组的临床特点、免疫分型分期、MRD、危险分层和总体生存率等进行比较。采用χ2检验、t检验、方差分析以及生存分析进行统计学分析。结果初发B-ALL患儿共125例,CD20阳性组48例,阴性组77例,中位年龄6岁,中位随访时间为30个月。多因素COX分析显示CD20的表达与年龄、性别、初发时的白细胞计数、融合基因、免疫表型分期以及危险分层等均无差别; CD20阳性组患儿的第35天MRD阳性发生率为35.4%,明显大于CD20阴性组的16.9%,差异有统计学意义(χ2=5.236,P<0.05),而总体生存率(OS)为75.0%,明显小于CD20阴性组的84.4%,差异有统计学意义(χ2=4.160,P<0.05)。结论初发B-ALL的CD20阳性表达与ALL总体生存率低相关,可能为联合选择美罗华靶点的治疗方案提供依据。(中华检验医学杂志,2014,37:447-450)
目的:分析兒童B繫急性淋巴細胞性白血病( B-ALL)中CD20錶達和臨床特點,探索CD20在評估預後中的作用。方法2008年11月至2012年7月上海市兒童醫院初診125例B繫兒童急性淋巴細胞性白血病患兒,男79例,女46例,年齡2箇月~14歲,所有患兒均應用流式細胞儀進行初診時的免疫分型和微小殘留病變( MRD)篩選,對存在MRD標記的患兒在誘導緩解的第35天進行MRD鑑測。根據CD20錶達將B-ALL患兒分為CD20暘性組和CD20陰性組,對各組的臨床特點、免疫分型分期、MRD、危險分層和總體生存率等進行比較。採用χ2檢驗、t檢驗、方差分析以及生存分析進行統計學分析。結果初髮B-ALL患兒共125例,CD20暘性組48例,陰性組77例,中位年齡6歲,中位隨訪時間為30箇月。多因素COX分析顯示CD20的錶達與年齡、性彆、初髮時的白細胞計數、融閤基因、免疫錶型分期以及危險分層等均無差彆; CD20暘性組患兒的第35天MRD暘性髮生率為35.4%,明顯大于CD20陰性組的16.9%,差異有統計學意義(χ2=5.236,P<0.05),而總體生存率(OS)為75.0%,明顯小于CD20陰性組的84.4%,差異有統計學意義(χ2=4.160,P<0.05)。結論初髮B-ALL的CD20暘性錶達與ALL總體生存率低相關,可能為聯閤選擇美囉華靶點的治療方案提供依據。(中華檢驗醫學雜誌,2014,37:447-450)
목적:분석인동B계급성림파세포성백혈병( B-ALL)중CD20표체화림상특점,탐색CD20재평고예후중적작용。방법2008년11월지2012년7월상해시인동의원초진125례B계인동급성림파세포성백혈병환인,남79례,녀46례,년령2개월~14세,소유환인균응용류식세포의진행초진시적면역분형화미소잔류병변( MRD)사선,대존재MRD표기적환인재유도완해적제35천진행MRD감측。근거CD20표체장B-ALL환인분위CD20양성조화CD20음성조,대각조적림상특점、면역분형분기、MRD、위험분층화총체생존솔등진행비교。채용χ2검험、t검험、방차분석이급생존분석진행통계학분석。결과초발B-ALL환인공125례,CD20양성조48례,음성조77례,중위년령6세,중위수방시간위30개월。다인소COX분석현시CD20적표체여년령、성별、초발시적백세포계수、융합기인、면역표형분기이급위험분층등균무차별; CD20양성조환인적제35천MRD양성발생솔위35.4%,명현대우CD20음성조적16.9%,차이유통계학의의(χ2=5.236,P<0.05),이총체생존솔(OS)위75.0%,명현소우CD20음성조적84.4%,차이유통계학의의(χ2=4.160,P<0.05)。결론초발B-ALL적CD20양성표체여ALL총체생존솔저상관,가능위연합선택미라화파점적치료방안제공의거。(중화검험의학잡지,2014,37:447-450)
Objective To analyzed the expression and clinical characteristics of CD 20 marker in children with B-lineage acute lymphoblastic leukemia ( B-ALL) and evaluated its medical significance in assessing the prognosis of disease.Methods From November 2008 to July 2012,125 cases of children with B-lineage acute lymphoblastic leukemia were collected from Shanghai Children ′s Hospital,including 79 males and 46 females, aged between 2 months to 14 years old.Flow cytometry based immunophenotyping and Minimal Residual Disease ( MRD) screening were applied to these children when newly diagnosed ,and MRD monitoring was again carried out after 35 days of induction remission therapy to those bears the MRD markers.These 125 patients were divided into CD20-positive group and CD20-negative group, and the corresponding clinical characteristics ,stage of immunophenotype ,MRD,risk stratification,and overall survival rates were recorded and compared.Data were statistically analyzed by using SPSS 16.0 software including χ2 test,t-test,standard deviation test and survival test.Results A total of 125 children with ALL-B,the group of CD20-positive were 48 while CD20-negative groups were 77,with a median age of 6 years old,and the median follow-up time of 30 months.Multivariate Cox regression Analysis showed that there was no clear correlation between CD20 expression level with age ,sex,white blood cell count at diagnosis ,fusion-gene,the stage of immunophenotype as well as risk stratification.The MRD-positive incidence at 35 days in the CD20 positive group was 35.4%,much higher than that of the CD20-negative group (16.9%),which is statistical significance (χ2 =5.236,P<0.05),while the overall survival rate (OS) for the CD20 positive group is 75.0%,much lower than that of the CD20 negative group (84.4%,χ2 =4.160,P<0.05).Conclusions CD20 positive expression level in children with B-lineage acute lymphoblastic leukemia at diagnosis demonstrates negative correlation with the overall survival rate of the patient ,indicating its usefulness as an additional joint marker for the current regimens to incorporate CD 20-targeted monoclonal therapy.